Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Custom...

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.  PR Newswire

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High - Still a Buy? - Mark...

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High - Still a Buy?  MarketBeat

Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance

Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership  Yahoo Finance

Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake - Bloomberg.com

Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake  Bloomberg.com

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake  Reuters

Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused ...

Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company  Fierce Pharma

GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - GSK

GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding  GSK

Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release - lupin.com

Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release  lupin.com

Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology

Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up  Pharmaceutical Technology

The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the N...

The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation  Shionogi Inc.

Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer - Pharmaceutical Executive

Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer  Pharmaceutical Executive

[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - Europ...

[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding  European AIDS Treatment Group

Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share - B...

Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share  BioXconomy

Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADI...

Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA  Cleary Gottlieb

Results: Shionogi & Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts - si...

Results: Shionogi & Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts  simplywall.st

Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum...

Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum  Yahoo Finance

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierc...

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business  Fierce Pharma

All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy  Yahoo Finance

ALS med Radicava to change hands as Shionogi inks $2.5B buyout - Fierce Pharma

ALS med Radicava to change hands as Shionogi inks $2.5B buyout  Fierce Pharma

Why Shionogi (TSE:4507) Is Up 6.2% After Profit Growth Outpaced Sales In Latest Results – And Wha...

Why Shionogi (TSE:4507) Is Up 6.2% After Profit Growth Outpaced Sales In Latest Results – And What's Next  Yahoo Finance

Pfizer Cashes In ViiV Stake With Shionogi Sale For $1.88bn - Citeline News & Insights

Pfizer Cashes In ViiV Stake With Shionogi Sale For $1.88bn  Citeline News & Insights

Shionogi & Co. (SGIOF) Price Target Increased by 19.88% to 20.86 - Nasdaq

Shionogi & Co. (SGIOF) Price Target Increased by 19.88% to 20.86  Nasdaq

Pfizer sells ViiV stake to Shionogi - The Pharma Letter

Pfizer sells ViiV stake to Shionogi  The Pharma Letter

Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal - FirstWord Pharma

Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal  FirstWord Pharma

Shionogi to buy Jersey City pharma for $2.5B - NJBIZ

Shionogi to buy Jersey City pharma for $2.5B  NJBIZ

Shionogi to acquire ALS medications from Tanabe - The Pharma Letter

Shionogi to acquire ALS medications from Tanabe  The Pharma Letter

Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld MedTech

Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more  BioWorld MedTech

Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug - FirstWord Pharma

Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug  FirstWord Pharma

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention  Contagion Live

Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug - BioP...

Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug  BioPharma Dive

Shionogi (TSE:4507) Q3 Net Margin Strength Challenges Cautious Earnings Growth Narratives - simpl...

Shionogi (TSE:4507) Q3 Net Margin Strength Challenges Cautious Earnings Growth Narratives  simplywall.st

Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma...

Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA  Business Wire

Enrollment Update - Shionogi Inc.

Enrollment Update  Shionogi Inc.

Shionogi & Co: Strong revenue and profit growth, boosted by acquisitions and robust royalty incom...

Shionogi & Co: Strong revenue and profit growth, boosted by acquisitions and robust royalty income  TradingView

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Issues Quarterly Earnings Results, Beats Est...

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS  MarketBeat

Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance - Fierce Pharma

Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance  Fierce Pharma

Can Shionogi’s Rally Continue After Key Drug Approval in 2025? - Yahoo Finance

Can Shionogi’s Rally Continue After Key Drug Approval in 2025?  Yahoo Finance

Shionogi moves to acquire global rights to Radicava for ALS - ALS News Today

Shionogi moves to acquire global rights to Radicava for ALS  ALS News Today

Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi - Yahoo Finance

Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi  Yahoo Finance

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact - BioWorld MedTech

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact  BioWorld MedTech

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP  Infectious Disease Special Edition

Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain - Yahoo Fi...

Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain  Yahoo Finance

Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook - TipRanks

Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook  TipRanks

Shionogi Lifts Revenue and Profit on Royalty Growth and Overseas Expansion - TipRanks

Shionogi Lifts Revenue and Profit on Royalty Growth and Overseas Expansion  TipRanks

BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology

BioVersys and Shionogi agree to develop ansamycin leads  Pharmaceutical Technology

Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - WTVB

Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits  WTVB

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure  Business Wire

GSK, Pfizer and Shionogi agree on ViiV Healthcare shareholding changes - Investing.com

GSK, Pfizer and Shionogi agree on ViiV Healthcare shareholding changes  Investing.com

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program  Fierce Biotech

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume - What's ...

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume - What's Next?  MarketBeat

Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook - The Globe and Mail

Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook  The Globe and Mail

Shionogi to increase stake in ViiV Healthcare as Pfizer exits - Investing.com

Shionogi to increase stake in ViiV Healthcare as Pfizer exits  Investing.com

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - MSN

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake  MSN

Recon: FDA approves Cytokinetics’ heart drug in first for drugmaker; Shionogi forges $2.5 billion...

Recon: FDA approves Cytokinetics’ heart drug in first for drugmaker; Shionogi forges $2.5 billion buyout of Tanabe Pharma’s ALS therapy Radicava  Regulatory Affairs Professionals Society | RAPS

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon - simplywall.st

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon  simplywall.st

GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia

GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare  BioSpectrum Asia

Pfizer to depart GSK’s ViiV as Shionogi doubles its stake - Endpoints News

Pfizer to depart GSK’s ViiV as Shionogi doubles its stake  Endpoints News

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge  JAPAN Forward

Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake - Seeking Alpha

Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake  Seeking Alpha

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculou...

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate  Yahoo Finance

Shionogi expands rare disease presence with acquisition of global rights to Tanabe’s RADICAVA for...

Shionogi expands rare disease presence with acquisition of global rights to Tanabe’s RADICAVA for $2.5 B  BioSpectrum Asia

Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma

Shionogi strikes research and option deal with BioVersys for antibacterial assets  FirstWord Pharma

Shionogi & Co (4507 JP): Decent 9MFY26 Result; No Revision in FY Forecast; Accelerate Growth Ahea...

Shionogi & Co (4507 JP): Decent 9MFY26 Result; No Revision in FY Forecast; Accelerate Growth Ahead  Smartkarma

Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug - MarketWatch

Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug  MarketWatch

GSK and Shionogi Restructure Stake in ViiV Healthcare - GuruFocus

GSK and Shionogi Restructure Stake in ViiV Healthcare  GuruFocus

Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum

Shionogi puts up to $600m behind BioVersys antibiotics  pharmaphorum

Shionogi inks hearing loss deal with Salubritas Therapeutics - The Pharma Letter

Shionogi inks hearing loss deal with Salubritas Therapeutics  The Pharma Letter

Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College...

Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners  Imperial College Healthcare NHS Trust

Shionogi’s Oral RSV Antiviral Moves Forward: What Investors Should Watch in This Phase 2b Trial -...

Shionogi’s Oral RSV Antiviral Moves Forward: What Investors Should Watch in This Phase 2b Trial  TipRanks

Shionogi lifts profit outlook on HIV royalties and overseas growth - The Japan Times

Shionogi lifts profit outlook on HIV royalties and overseas growth  The Japan Times

Shionogi to buy Japan Tobacco's pharma units for over $1B - FirstWord Pharma

Shionogi to buy Japan Tobacco's pharma units for over $1B  FirstWord Pharma

Japan's Shionogi pays $2.13B to boost stake in ViiV Healthcare - Latest news from Azerbaijan

Japan's Shionogi pays $2.13B to boost stake in ViiV Healthcare  Latest news from Azerbaijan

Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits - Indian Pharma Post

Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits  Indian Pharma Post

GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share - In...

GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share  Investing.com

Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter

Shionogi pushes 2030 vision forward with $1 billion acquisition  The Pharma Letter

BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter

BioVersys joins forces with Shionogi on ansamycin development  The Pharma Letter

Qpex Biopharma’s New President Wants More Push-Pull Incentives, Opportunities for Young US Scient...

Qpex Biopharma’s New President Wants More Push-Pull Incentives, Opportunities for Young US Scientists  Contagion Live

Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK - MedCity News

Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK  MedCity News

Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture - TipRanks

Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture  TipRanks

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - TradingView

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake  TradingView

Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech

Bioversys, Shionogi in CHF529M lung infection collaboration  BioWorld MedTech

Shionogi’s Fetroja launches in Japan - The Pharma Letter

Shionogi’s Fetroja launches in Japan  The Pharma Letter

Gareth Morgan Named President of Qpex Biopharma, Inc. - Business Wire

Gareth Morgan Named President of Qpex Biopharma, Inc.  Business Wire

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs  Bloomberg.com

Shionogi to increase stake in ViiV Healthcare as Pfizer exits By Investing.com - Investing.com Ni...

Shionogi to increase stake in ViiV Healthcare as Pfizer exits By Investing.com  Investing.com Nigeria

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - Bloomberg Law News

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug  Bloomberg Law News

GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare - TipRanks

GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare  TipRanks

Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe - Citeline News & In...

Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe  Citeline News & Insights

Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum

Shionogi aims to buy tobacco giant's pharma unit for $1bn  pharmaphorum

Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer - markets...

Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer  marketscreener.com

All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy - sharewise.com

All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy  sharewise.com

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - marketscreener.com

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake  marketscreener.com

Yomiuri: Shionogi to Acquire ALS Drug Business from Tanabe Pharma for 2.5 Billion Dollars - Marke...

Yomiuri: Shionogi to Acquire ALS Drug Business from Tanabe Pharma for 2.5 Billion Dollars  MarketWatch

GSK and Shionogi Buy Out Pfizer’s Stake in HIV Specialist ViiV Healthcare - TipRanks

GSK and Shionogi Buy Out Pfizer’s Stake in HIV Specialist ViiV Healthcare  TipRanks

Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech

Shionogi to acquire Japan Tobacco pharma companies for $1.1B  BioWorld MedTech

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral  The Pharma Letter

Pfizer Sells ViiV Stake for USD 1.9 Billion, Shionogi Emerges Bigger Partner - Medical Dialogues

Pfizer Sells ViiV Stake for USD 1.9 Billion, Shionogi Emerges Bigger Partner  Medical Dialogues

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs - Nikkei Asia

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs  Nikkei Asia

Shionogi & Co.'s Nine-Month Profit Jumps 18% - 富途牛牛

Shionogi & Co.'s Nine-Month Profit Jumps 18%  富途牛牛

Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy

Eyes on Asia: Chugai, Mabwell, Shionogi  BioXconomy